Athersys (NASDAQ:ATHX) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Thursday, January 10th.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Athersys from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 8th. BidaskClub raised Athersys from a “sell” rating to a “hold” rating in a research report on Wednesday, September 26th.
Athersys stock traded up $0.02 during trading on Thursday, hitting $1.43. 558,748 shares of the company were exchanged, compared to its average volume of 467,073. Athersys has a 52 week low of $1.29 and a 52 week high of $3.09. The company has a market capitalization of $199.86 million, a P/E ratio of -4.93 and a beta of 0.03.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.01. Athersys had a negative return on equity of 58.74% and a negative net margin of 108.83%. The business had revenue of $2.32 million during the quarter, compared to the consensus estimate of $1.80 million. On average, sell-side analysts anticipate that Athersys will post -0.19 EPS for the current fiscal year.
In related news, EVP John J. Harrington sold 15,000 shares of the stock in a transaction dated Friday, December 14th. The stock was sold at an average price of $1.93, for a total transaction of $28,950.00. Following the completion of the sale, the executive vice president now directly owns 660,270 shares in the company, valued at approximately $1,274,321.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 18.60% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of ATHX. Marshall Wace LLP purchased a new stake in Athersys during the 3rd quarter valued at about $59,000. Schwab Charles Investment Management Inc. lifted its holdings in Athersys by 50.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 250,900 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 84,600 shares during the period. Alps Advisors Inc. lifted its holdings in Athersys by 22.5% in the 3rd quarter. Alps Advisors Inc. now owns 245,240 shares of the biopharmaceutical company’s stock worth $515,000 after buying an additional 45,024 shares during the period. Renaissance Technologies LLC lifted its holdings in Athersys by 21.3% in the 2nd quarter. Renaissance Technologies LLC now owns 439,900 shares of the biopharmaceutical company’s stock worth $867,000 after buying an additional 77,100 shares during the period. Finally, Millennium Management LLC lifted its holdings in Athersys by 377.6% in the 2nd quarter. Millennium Management LLC now owns 457,667 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 361,835 shares during the period. Institutional investors own 19.55% of the company’s stock.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Recommended Story: How does the Federal Reserve determine interest rates?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Athersys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Athersys and related companies with MarketBeat.com’s FREE daily email newsletter.